Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) dropped 0.8% during mid-day trading on Monday . The stock traded as low as $1.02 and last traded at $1.04. Approximately 36,122 shares were traded during trading, an increase of 38% from the average daily volume of 26,181 shares. The stock had previously closed at $1.04.
Connect Biopharma Trading Down 0.8 %
The business has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.18.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Connect Biopharma stock. BML Capital Management LLC boosted its holdings in Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,093,232 shares of the company's stock after purchasing an additional 49,984 shares during the quarter. Connect Biopharma accounts for about 1.8% of BML Capital Management LLC's portfolio, making the stock its 13th largest holding. BML Capital Management LLC owned approximately 3.79% of Connect Biopharma worth $3,014,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 58.72% of the company's stock.
About Connect Biopharma
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
See Also
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
